CN103735591B - A kind of compositions of anti-peptic ulcer and application thereof - Google Patents
A kind of compositions of anti-peptic ulcer and application thereof Download PDFInfo
- Publication number
- CN103735591B CN103735591B CN201310680958.5A CN201310680958A CN103735591B CN 103735591 B CN103735591 B CN 103735591B CN 201310680958 A CN201310680958 A CN 201310680958A CN 103735591 B CN103735591 B CN 103735591B
- Authority
- CN
- China
- Prior art keywords
- spirulina
- polysaccharide
- compositions
- atractylis concrete
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a kind of pharmaceutical composition of anti-peptic ulcer.Described pharmaceutical composition contains the spirulina polysaccharide of effective dose, atractylis concrete and pharmaceutically acceptable pharmaceutic adjuvant, and this pharmaceutical composition can be used for medicine or the functional food of preparing prevention or treatment gastric ulcer.
Description
Technical field
The invention belongs to medicine and food compositions field, particularly, relate to a kind of pharmaceutical composition containing spirulina polysaccharide and atractylis concrete, and the preparation method of described pharmaceutical composition and the application in the medicine or food of preparation treatment or prevention peptic ulcer thereof.
Technical background
Spirulina (Spirulina) is Cyanophyta, Oscillatoriales, Oscillariaceae, Spirullina lower algae plant, is unicellular and cellulous filamentous microorganism, filament helical form.The spirulina found at present has more than 35 kinds, and all have growth at fresh water and salt water, the spirulina wherein for food production mainly contains spirulina plalensis (Spirulinaplatensis) and spirulina maxim (Spirulinamaxima).
Spirulina polysaccharide be separated from spirulina, a kind of water solublity heteropolysaccharide of purification, modern times research data its there is antiviral, Hangzhoupro tumor, Hangzhoupro oxidation, Hangzhoupro radiation, Hangzhoupro suddenlys change and the multiple biological medicine function such as enhancing immunity.
According to " Chinese Pharmacopoeia " (2010 editions), Rhizoma Atractylodis refer to the dry rhizome of Compositae [WTBX plant Atractylodes lancea (Thunb.) DC. (RHIZOMA ATRACTYLODIS IANCEAE) Atractylodeslancea, Atractylis chinensis Atractylodeschinensis.In addition, the congener used as medicinal plants also comprises atractylodes japonica Atractylodesjaponica, Atractylodes koreana A.koreana, full leaf Rhizoma Atractylodis A.chinensis, Chifeng Rhizoma Atractylodis A.Chinensis.
Rhizoma Atractylodis have the Chinese medicine tradition applicating history of thousands of years.Chinese Traditional Medicine document is recorded, and Rhizoma Atractylodis acrid in the mouth, hardship are warm in nature, return spleen, stomach, Liver Channel, have drying damp and strengthening spleen, wind-damp dispelling, effect of improving eyesight.Be mainly used in distension and fullness in the abdomen, have loose bowels, edema, beriberi flaccidity syndrome and arthralgia syndrome, rheumatic arthralgia, anemofrigid cold, nyctalopia nyctalopia.
Peptic ulcer mainly refers to betide stomach and duodenal chronic ulcer, is a frequently-occurring disease, commonly encountered diseases, and total incidence can account for about 10% ~ 12% of population.The clinical characters of peptic ulcer is chronic process, intermittence, middle upper abdomen rhythmicity pain, its pathomechanism be the gastric acid of digest food and the pepsin digestion coat of the stomach of self and duodenal wall, thus damage harmonization of the stomach Duodenal Mucosa tissue cause disease.
In the pathogeny of peptic ulcer, gastroxia plays an important role.The gastric acid basal secretion amount of duodenal ulcer intestinal ulcer patient and maximal secretory capacity can apparently higher than ordinary persons; Duodenal ulcer never betides without gastric acid secretion or secretes little people, and BAO with MAO of gastric ulcer patient is all similar to normal person, even lower than normal person.
Helicobacter pylori (Helicobacterpylori, HP) infection is the Etiological of chronic gastritis, is the Important cause of disease causing peptic ulcer.The epithelial cell microvilli adhered at HP reduces, and Cell tracking is lost, cellular swelling, surface imperfection, and intracellular mucous granule is exhausted, cavity sample becomes, and antibacterial and iuntercellular form the adhere base of a fruit and tazza spline structure.
The remedy measures of peptic ulcer comprises feelings will, dietary adjustments and Drug therapy.
Antacid such as sodium bicarbonate, gel aluminum hydroxide, bismuth subcarbonate etc. can lower the acidity of Stomach duodenum, alleviating pain, promote ulcer healing.Anticholinergic atropine, propantheline, metoclopramide etc. can suppress vagus nerve and reduce gastric acid secretion, but it delays gastric emptying gastrin secretion can be caused to increase.Histamine H2-receptor antagonist cimetidine, famotidine etc. compete H2 receptor with histamine, eliminate histamine and cause gastric acid secretion effect.Acid pump inhibitor is as omeprazole (omeprazde, and lansoprazole (1anzoprazde OMP), and suppress helicobacter pylori medicine such as metronidazole and Li Fuxisheng to form triple therapy, to treat the peptic ulcer disease of the helicobacter pylori positive LAN).
Existing data display, spirulina polysaccharide to stress ulcer have preventive and therapeutic action (Wu little Mei etc., the experimentation of spirulina prevention stress in rats gastric ulcer. traffic medicine, 1997; 11 (2): 148-149), atractylodes japonica and Atractylodes lancea (Thunb.) DC. extract, Rhizoma Atractylodis mixture etc. to Experimental oral ulcer have antagonism (Zhu Donghai etc., Wild and cultivated Rhizoma Atractylodis are to the pharmacological research of Mus gastric ulcer model. CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2010; 35 (13): 1758-1762; Piao Shihao etc., the antiulcer action research of atractylodes japonica n-butyl alcohol extract. Chinese herbal medicine, 1996; 27 (7): 410-413; Ninghai appearance etc., the effect of Rhizoma Atractylodis Mixture ulcerative colitis in rats and Antioxidation Mechanism research, Zhongshan University's journal (medical science version), 2008; (3S): 169-171).
So far, in prior art, there is not the report of compositions atractylis concrete and spirulina polysaccharide are mixed with, do not have said composition can produce the report of collaborative antiulcer action yet.
Summary of the invention
The object of the present invention is to provide a kind of compositions atractylis concrete and spirulina polysaccharide are mixed with, the atractylis concrete of molten condition mixes with spirulina polysaccharide by the present invention, can obtain solid mixture under room temperature; Gained volatile oil total polysaccharides mixture can produce collaborative antiulcer action, particularly has significant preventive and therapeutic action to the Experimental Gastric Ucler model caused by helicobacter pylori.In addition, the present invention is also provide the preparation method of said composition and preparing the application treated and/or prevented in Gastric Ulcer Treatment or food.
Following technical proposals of the present invention is for realizing above-mentioned goal of the invention:
First the present invention provides a kind of edible and/or Pharmaceutical composition, and described compositions contains acceptable excipient in spirulina polysaccharide extract, atractylis concrete and the medicine and/or food preparation preventing and/or treating gastric ulcer effective dose.Wherein:
Described spirulina polysaccharide extract is from Spirulina platensis and/or new strain SCS, extract the total polysaccharides obtained, and wherein, in described spirulina polysaccharide extract, total sugar content is not less than 80% of extract total amount; The mean molecule quantity of polysaccharide is not less than 10kD.
Described atractylis concrete extracts the total volatile oil obtained from Rhizoma Atractylodis AtractylodesLances dry rhizome, and wherein the content sum of atractylol and eudesmol is not less than 50% of volatile oil total amount.
The proportion of composing of described spirulina polysaccharide and atractylis concrete is in the scope of 5:1 ~ 5:4.
Edible and/or Pharmaceutical composition of the present invention refers to that compositions of the present invention both can be used as functional food, also can be used as the pharmaceutical composition of prevention and therapy peptic ulcer.
Spirulina polysaccharide of the present invention can optionally extract from Spirulina platensis and/or new strain SCS.Experimental studies results display of the present invention, can produce approximate antiulcer activity by the pharmaceutical composition that spirulina platensis polysaccharide and/or spirulina maxim polysaccharide are used for the present invention.
In the [WTBX plant drying rhizome of different plant species, the chemical composition composition of contained volatile oil differs greatly, and atractylis concrete of the present invention refers to from Atractylodes lancea (Thunb.) DC. and extracts also known as RHIZOMA ATRACTYLODIS IANCEAE AtractylodesLances dry rhizome the volatile oil obtained.In described atractylis concrete, with mass ratio range, the content sum of atractylol (hinesol) and eudesmol (β-eudesmol) is not less than 50% of volatile oil total amount.Atractylol (hinesol) and eudesmol (β-eudesmol) as follows.
Atractylol contained by atractylis concrete and β-eudesmol confirm by chromatography of gases-GC-MS, and its content detects by gas chromatography.
The present invention studies discovery, and when the proportion of composing of spirulina polysaccharide and atractylis concrete is in the scope of 5:1 ~ 5:4, it is active that described compositions all has good collaborative anti-experimental character gastric ulcer.In the preferred embodiment of the invention, the spirulina polysaccharide in pharmaceutical composition described in it and the proportion of composing of atractylis concrete are in the scope of 3:1 ~ 3:2.
Present invention also offers the preparation method of described spirulina polysaccharide, described method comprises the steps:
(1) water extraction method obtains spirulina water extract;
(2) aqueous solution of step (1) gained spirulina water extract is obtained spirulina total polysaccharides through C1-C4 lower alcohol or ketone fractional precipitation;
(3) ultrafiltration or chromatographic methods step (2) gained spirulina total polysaccharides can be optionally adopted to obtain purification spirulina polysaccharide extract further.
In its step (1), it is generally with the water of about 8 ~ 15 times of weight that described water extraction extracts, and extracts 2 ~ 3 times under room temperature to 100 DEG C condition; Be for further processing after optionally obtained aqueous solution suitably can being concentrated;
In step (2), preferred rudimentary alcohol ketone comprises ethanol and acetone, after gained precipitation can optionally adopt rudimentary alcohol ketone to wash 1 ~ 3 time, adopts drying under reduced pressure, cryodesiccated method dry.
Step (2) gained total polysaccharides can be directly used in the preparation of the present composition.It will be understood by those skilled in the art that described total polysaccharides also can adopt ultrafiltration, gel chromatography, ion exchange chromatography to be further purified further.
According to the present invention's repeatedly repeated trials result of study, the neutral sugar content in gained spirulina polysaccharide extract is not less than 80% of total extract; High productivity computing method (HPGPC) testing result shows, due to the impact of raw material sources (manufacturer and production batch different) and degree of purification, the molecular weight of gained spirulina polysaccharide is not quite similar, but generally, its mean molecule quantity is all not less than 10kD.
The present invention also provides the preparation method of atractylis concrete described in claim 1 ~ 2 further, described method optionally can adopt (1) steam distillation, (2) supercritical extraction, (3) organic solvent extraction to extract and obtain total volatile oil, atractylis concrete namely of the present invention.
Described essential oil extraction method is well known to those skilled in the art, and wherein, steam distillation is conventional essential oil extraction method; And CO
2supercritical extraction can improve the extraction yield of volatile oil, but the fitter acids and its ester of high level can be contained in its product, it will be understood by those skilled in the art that the content of the fitter acids and its ester adopting the method such as crystallization, solvent extraction to reduce further or in partial removal supercritical extraction product.
The present invention also provides the solid preparation preparation method of pharmaceutical composition of the present invention, and its step comprises:
Make the atractylis concrete of amount of formulation be molten condition at (1) 60 DEG C ~ 80 DEG C, stir the spirulina polysaccharide adding amount of formulation ,-18 DEG C ~ 4 DEG C cold preservations make it to solidify, pulverize at low temperature;
(2) add the acceptable pharmaceutical excipient of physiology in step (1) products therefrom and granulate;
(3) by step (2) gained granulation or filled capsules.
Generally speaking, phytovolatilization oil component, due to its grease character, is prepared into soft capsule class preparation more, and solid preparation preparation has certain difficulty.The present invention finds, spirulina polysaccharide is uniformly mixed in the atractylis concrete under molten condition, when reducing temperature, the solid content being easy to pulverize can be obtained, after its solid content is pulverized, can easily with pharmaceutically acceptable mixed with excipients, and gained mix powder or granule can have good mobility, are therefore easy to prepare filled capsules or be pressed into tablet.
Described pharmaceutically acceptable excipient can include but not limited to filler, slip agents, binding agent, coloring agent etc.Also the coating such as coating materials, coloring agent can be optionally adopted for solid tablet.
The present invention studies proof, the gastric ulcer model of the compositions containing atractylis concrete and spirulina polysaccharide of the present invention caused by pylorus ligation, helicobacter pylori and chemical duodenal ulcer model all have the effect preventing and/or treating ulcer significantly, and its effect presents obvious synergism effect, the therefore purposes providing pharmaceutical composition of the present invention to prevent and/or treat in Gastric Ulcer Treatment in preparation further of the present invention.
Accompanying drawing explanation
Fig. 1 is the high productivity computing of spirulina platensis polysaccharide and spirulina maxim polysaccharide, (A: spirulina platensis polysaccharide; B: spirulina maxim polysaccharide);
Fig. 2 is atractylis concrete GC-MS spectrogram (A:GC spectrogram; B: atractylol MS spectrogram; C: β-eudesmol MS spectrogram).
Detailed description of the invention
The present invention, below in conjunction with accompanying drawing, is described further essentiality content of the present invention with specific embodiment.But these specific embodiments, only for illustration of the present invention, do not constitute any limitation scope of the present invention.
Embodiment 1:
Spirulina polysaccharide and atractylis concrete preparation:
1.1 spirulina polysaccharide preparations:
Get spirulina plalensis (Spirulinaplatensis) and each 1000g of spirulina maxim (Spirulinamaxima) dry powder, the defat of 95% (V/V) soak with ethanol, centrifugally remove ethanol, 15L water extraction twice at 80 DEG C, merge aqueous extract, be evaporated to extracting solution cumulative volume and be about 10L, add 30L95% (V/V) ethanol, hold over night at 4 DEG C, centrifugally must precipitate.Gained precipitation is dissolved respectively with 3L pure water, centrifugally remove insoluble matter, supernatant adjusts pH2.8 with 2NHCl, leaves standstill about 4hr at 4 DEG C, and centrifugal going precipitates (albumen), 2NNaOH adjusts pH neutral, add 9L95% (V/V) ethanol, hold over night at 4 DEG C, centrifugally must to precipitate, gained precipitation is with 2L90% washing with alcohol twice, and room temperature under reduced pressure drying obtains total polysaccharides respectively and is about 35.6g and 42.8g.
Getting spirulina plalensis total polysaccharides 20g is dissolved in 650ml pure water, and 3kD ultrafilter membrane (Millipore ultrafiltration apparatus) ultrafiltration, retains solution lyophilization and obtain spirulina platensis polysaccharide 18.5g;
Separately get spirulina maxim total polysaccharides 20g, be dissolved in 650ml pure water, cross Sephadex-G50 gel chromatographic columns (Ф 8cmx150cm) purification, collect containing after saccharic composition, lyophilization obtains spirulina maxim total polysaccharides 15.3g.
The sugared content that Phenol-sulphate acid method detects in described spirulina plalensis total polysaccharides, spirulina platensis polysaccharide, spirulina maxim total polysaccharides, spirulina maxim polysaccharide is respectively 86.4%, 89.8%, 85.3% and 91.5%.
Take dextran standards as standard, the molecular weight that high productivity computing (HPGPC) method detects described spirulina platensis polysaccharide and spirulina maxim polysaccharide is respectively about 16.7kD and 28.6kD.
The HPGPC that accompanying drawing 1A and 1B is depicted as spirulina platensis polysaccharide and spirulina maxim polysaccharide detects collection of illustrative plates.
1.2 atractylis concrete preparations
Method: get the Atractylodes lancea (Thunb.) DC. AtractylodesLances dry rhizome granule three parts of each 1kg pulverized, is respectively used to vapor distillation extraction, organic solvent extraction and CO
2supercritical extraction.Wherein:
(1) vapor distillation extracts is insert in the port grinding bottle of volatile oil extractor by 1kg Atractylodes lancea (Thunb.) DC. dry rhizome granule, by Chinese Pharmacopoeia annex method continuous still 5 hours, then stops heating, discharges water after cooling, collect the grease on distillate surface.
(2) organic solvent extraction is inserted in flask by 1kg Atractylodes lancea (Thunb.) DC. dry rhizome granule, and using normal hexane as solvent, reflux, extract, 8h, distilling under reduced pressure, except desolventizing, obtains extracting product.
(3) CO
2supercritical extraction is that 1kg Atractylodes lancea (Thunb.) DC. dry rhizome granule is put into Supercritical Fluid Extractor, flow ~ 35kg/h, static extracting 1hr, dynamic extraction 3hr under temperature ~ 50 DEG C, pressure ~ 20MPa.At separating pressure ~ 10MPa, at temperature 40 DEG C, separate out volatile oil.
Gas chromatography analytic process detects the content of atractylol and β-eudesmol in three kinds of extraction method gained atractylis concretes, and the chromatographic condition of described detection is, HP-5MS chromatographic column, quartz capillary column (30m × 250 μm × 0.25 μm); Vaporizer temperature 280 DEG C; Mass detector, ion source temperature 230 DEG C; Quadrupole rod temperature 150 DEG C; Column temperature (temperature programming): 80 DEG C (1min), 12 DEG C/min is warming up to 280 DEG C (15min); Split ratio 1:100; Carrier gas He, flow 1.5ml/min.
Result: steam distillation obtain atractylis concrete be about 28.3g, products therefrom at low temperatures (20 DEG C or following) in light yellow decorating film.Gas chromatography detects, and the content sum of its atractylol and β-eudesmol is about 72.3%.
Normal hexane extraction method obtains atractylis concrete and is about 28.3g, and products therefrom is the yellow oil of thickness.Gas chromatography detects, and the content sum of its atractylol and β-eudesmol is about 55.5%;
CO
2supercritical extraction obtain atractylis concrete be about 41.6g, products therefrom at low temperatures (20 DEG C or following) in light yellow decorating film.Gas chromatography detects, and the content sum of its atractylol and β-eudesmol is about 69.2%.
The gas chromatography-mass spectrum (GC-MS) of steam distillation acquisition atractylis concrete is analyzed collection of illustrative plates and is seen accompanying drawing 2, calculates its main constituent content as shown in table 1 according to GC-MS:
Atractylis concrete main chemical compositions GC-MS prepared by table 1. steam distillation analyzes
Embodiment 2:
Spirulina polysaccharide-atractylis concrete compositions is to the therapeutical effect of peptic ulcer model
2.1 rat Pylorus Ligated Gastric Ulcer models
Test specimen:
Spirulina polysaccharide, spirulina platensis polysaccharide described in embodiment 1;
Atractylis concrete, 1.2 described extraction by steam distillation products of embodiment 1;
Compositions A, its for weight ratio be the spirulina platensis polysaccharide of 2:1 and the mixture of steam distillation gained atractylis concrete.
Compositions B, its for weight ratio be the mixture of the spirulina maxim polysaccharide of 5:1 and the atractylis concrete of normal hexane extraction.
Compositions C, its for weight ratio be the mixture of the spirulina maxim polysaccharide of 5:4 and the atractylis concrete of supercritical extraction.
Test method: body weight 160 ~ 180gSD rat 64, be divided at random 8 groups (often organizing 8), i.e. model control group, spirulina polysaccharide administration group, atractylis concrete administration group, spirulina polysaccharide-Rhizoma Atractylodis water volatile-oil composite administration group (establishes A respectively, 200mg/kg, A, 100mg/kg, B, 200mg/kg, C, 100mg/kg administration group), positive controls (50mg/kg ranitidine).
Test first 48 hours Rat Fast and can't help water.During test, after rat anesthesia is fixing, sterile working's ligation pylorus.Postoperative each test group animal corresponding test medicine of gavage respectively, positive controls gavage ranitidine, model group gives the solvent of equivalent by the same method, and stops water supply for food.
Put to death rat after 18 hours, open abdominal cavity, nearly diaphragm place ligation esophagus, gets stomach and fixes 10 minutes in 1% formalin.Cut coat of the stomach along greater gastric curvature, clean content, launch coat of the stomach and be fixed on stencil plate with pin, observe gastric mucosa face, record according to a conventional method and often organize ulcer number of animals, ulcer area and ulcer index.
Result of the test: experimental result is in table 1.
Result shows, compares with model group, and except spirulina polysaccharide group, the Mus number of each administration group generation ulcer reduces to some extent, ulcer level significantly alleviates, and ulcer area reduces, and ulcer index reduces.The antiulcer result display of compositions A, the pharmacodynamic action of spirulina polysaccharide-atractylis concrete compositions is obviously better than the individually dosed drug effect of corresponding spirulina polysaccharide, Rhizoma Atractylodis water volatile oil, and its drug effect has the pharmacodynamics effect of Synergistic.The pharmacodynamic experiment result of compositions B and compositions C shows, spirulina platensis polysaccharide and spirulina maxim polysaccharide coupling atractylis concrete all can produce synergistic function; Vapor distillation, supercritical extraction and organic solvent extraction gained atractylis concrete all have antiulcer action.
Table 2. rat Pylorus Ligated Gastric Ulcer animal model test result
2.2 helicobacter pylori cause rat gastric ulcer model
Test specimen: spirulina polysaccharide atractylis concrete compositions D, its for weight ratio be the spirulina platensis polysaccharide of 3:2 and the mixture of steam distillation gained atractylis concrete.
Test method: body weight 160 ~ 180gSD rat 40.Rat Fast 24hr, after anaesthetized with pentobarbital, cuts open the belly, and dip glacialacetic acid dipping gastric antrum portion serosal surface twice, each 30s with diameter 5.5mm filter paper, normal saline cotton balls is put on the skin and washed burn site 3 times, sews up abdominal cavity, postoperative general nursing.Postoperative 3 days, gavage helicobacter pylori HP10 after Rat Fast 24hr
9cFUP/ only, continuous four day afterwards every day gavage HP, totally 5 times.
After modeling, rat is divided at random 4 groups (often organizing 10), i.e. model control group, the compositions D administration group of 250mg/kg and 125mg/kg dosage, positive controls (bismuth potassium citrate sheet/tinidazole tablets/clarithromycin tablet, 75mg/kg).The continuous gastric infusion of each administration group 7 days, model group gives equal-volume normal saline.Within after last perfusion 2 weeks, put to death animal, get stomach and observe and calculate ulcer index; Get the existence that gastric antrum portion tissue is urease dependence test (RUT) checking experiment animal Hp simultaneously.
Experimental result: spirulina polysaccharide atractylis concrete compositions D infects HP and has significant inhibitory action, has good therapeutical effect to glacial acetic acid-HP infective ulcer model of burning.
Table 3. rat Pylorus Ligated Gastric Ulcer animal model test result
2.3 experimental rat duodenal ulcer models
Test specimen: spirulina polysaccharide atractylis concrete compositions D, its for weight ratio be the spirulina platensis polysaccharide of 3:2 and the mixture of steam distillation gained atractylis concrete.
Test method: body weight 160 ~ 180gSD rat 40.After Rat Fast can't help water 12hr, the 10%L-aminothiopropionic acid hydrochlorate of rat neck dorsal sc injection 300mg/kg dosage, the 10%L-aminothiopropionic acid hydrochlorate of subcutaneous injection 200mg/kg again after 6hr.Rat was divided into 4 groups (often organizing 10) at random in postoperative 4th day, i.e. model control group, the compositions D administration group of 240mg/kg and 120mg/kg dosage, positive controls (ranitidine, 40mg/kg).Postoperative 5th day starts gastric infusion, and every bu gives described dosage 2 times.Model control group gives to wait capacity normal saline.Administration is after 10 days, and animal put to death by disconnected vertebra, and ligation pylorus and cardia, take out and be separated duodenum.Cut off duodenum along mesoduodenum offside, record area also calculates duodenal ulcer index.
Experimental result: experimental result shown in table 3 shows, and spirulina polysaccharide atractylis concrete compositions D causes Duodenal Ulcers In Rats to cysteine hydrochloride significant protective effect.
Table 4. Duodenal Ulcers In Rats animal model test result
Embodiment 3:
The preparation of spirulina polysaccharide atractylis concrete compositions and preparation method
3.1 solid tablet preparations
Prescription:
Method for making: the Rhizoma Atractylodis oil of melting at 60 DEG C, adds spirulina polysaccharide in stirring, 0 DEG C of left overnight, gained solid content pulverizes (80 order), add recipe quantity dextrin mixing granulation, gained granule adds the mixing of recipe quantity magnesium stearate, conventional method tabletted tablet.
3.2 hard capsule preparations
Prescription:
Method for making: the atractylis concrete of melting at 60 DEG C, spirulina polysaccharide is added in stirring, 0 DEG C of left overnight, gained solid content pulverizes (80 order), adds recipe quantity lactose, dextrin mix homogeneously, adds the HPMC solution prepared in advance and make soft material, 20 mesh sieves are granulated, 60 DEG C of dryings about 30 minutes, 18 mesh sieve granulate, dress 2# capsule.
Embodiment 3 two dosage forms, also can use as food.
Claims (7)
1. a compositions, by prevent or treat the spirulina polysaccharide extract of peptic ulcer effective dose, atractylis concrete and medicine or food prepare in acceptable excipient form, wherein:
Described spirulina polysaccharide extract is that the total sugar content extracted from Spirulina platensis and/or new strain SCS is not less than 80% of extract total amount, and the mean molecule quantity of polysaccharide is not less than the total polysaccharides of 10kD;
Described atractylis concrete is the total volatile oil being not less than volatile oil total amount 50% from the wherein atractylol of Rhizoma Atractylodis Atractylodeslancea extraction and the content sum of eudesmol;
The composition weight ratio of described spirulina polysaccharide and atractylis concrete is within the scope of 5:1 ~ 5:4.
2. compositions as claimed in claim 1, the composition weight ratio of wherein said spirulina polysaccharide and atractylis concrete is within the scope of 3:1 ~ 3:2.
3. compositions as claimed in claim 1 or 2, wherein the preparation method of spirulina polysaccharide is:
(1) water extraction method obtains spirulina water extract;
(2) aqueous solution of step (1) gained spirulina water extract is obtained spirulina total polysaccharides through C1-C4 lower alcohol or ketone fractional precipitation;
(3) step (2) gained spirulina total polysaccharides is carried out hyperfiltration treatment or chromatographic purification acquisition spirulina polysaccharide extract.
4. compositions as claimed in claim 1 or 2, wherein the preparation method of atractylis concrete gets steam distillation or supercritical extraction or organic solvent extraction.
5. compositions as claimed in claim 1 or 2, wherein the preparation method of solid preparation is:
Make the atractylis concrete of recipe quantity be molten condition at (1) 60 DEG C ~ 80 DEG C, stir the spirulina polysaccharide adding recipe quantity ,-18 DEG C ~ 4 DEG C cold preservations make it to solidify, pulverize at low temperature;
(2) pharmacologically acceptable pharmaceutical excipient granulating is added in step (1) products therefrom;
(3) by step (2) gained granulation or filled capsules.
6. the application of compositions described in claim 1 or 2 in preparation prevention or treatment digestive ulcer medicament.
7. the application of compositions described in claim 1 or 2 in preparation prevention or treatment peptic ulcer food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310680958.5A CN103735591B (en) | 2013-12-12 | 2013-12-12 | A kind of compositions of anti-peptic ulcer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310680958.5A CN103735591B (en) | 2013-12-12 | 2013-12-12 | A kind of compositions of anti-peptic ulcer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735591A CN103735591A (en) | 2014-04-23 |
| CN103735591B true CN103735591B (en) | 2016-04-06 |
Family
ID=50492706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310680958.5A Expired - Fee Related CN103735591B (en) | 2013-12-12 | 2013-12-12 | A kind of compositions of anti-peptic ulcer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735591B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106943450A (en) * | 2017-04-28 | 2017-07-14 | 苏州半部堂生物科技有限公司 | Containing astragalus polyose, the composition of atractylis concrete, preparation method and its usage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428086A (en) * | 2008-12-17 | 2009-05-13 | 遵义医学院 | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof |
| CN101439074A (en) * | 2008-12-11 | 2009-05-27 | 深圳海王药业有限公司 | Rhizoma atractylodis total terpene alcohol extract as well as preparation method and application thereof |
| CN103404758A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for gastric ulcer patients |
-
2013
- 2013-12-12 CN CN201310680958.5A patent/CN103735591B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439074A (en) * | 2008-12-11 | 2009-05-27 | 深圳海王药业有限公司 | Rhizoma atractylodis total terpene alcohol extract as well as preparation method and application thereof |
| CN101428086A (en) * | 2008-12-17 | 2009-05-13 | 遵义医学院 | Traditional Chinese medicine preparation for treating peptic ulcer and preparation method thereof |
| CN103404758A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for gastric ulcer patients |
Non-Patent Citations (2)
| Title |
|---|
| 茅苍术生物活性研究进展;冯慧等;《军医进修学院学报》;20081231;第29卷(第6期);552-554 * |
| 螺旋藻治疗消化性溃疡100例;吴世林等;《世界华人消化杂志》;20001031;第8卷(第10期);1194-1195 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735591A (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| KR20060100883A (en) | Composition having ginsenosides for treating or preventing diabetes | |
| CN113082166A (en) | Method for preparing health food from herba Dendrobii | |
| CN104523755B (en) | A kind of blattaria active component and its preparation method and application | |
| CN102526164A (en) | Traditional Chinese medicine composition for preventing insulin resistance and related metabolic syndrome thereof | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
| CN104857435B (en) | A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| CN103735591B (en) | A kind of compositions of anti-peptic ulcer and application thereof | |
| CN101254263A (en) | Compound Japanese polygala oral liquid and method of preparing the same | |
| CN114177244B (en) | Traditional Chinese medicine composition for treating thyroid cancer and preparation method thereof | |
| CN102370677A (en) | Three-flavor sandalwood preparation and preparation method thereof | |
| CN106535912A (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
| CN100350898C (en) | Diphase capsule of compound notoginseng and preparation method | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN108159204B (en) | Tibetan medicine composition with detoxifying and liver protecting effects | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN101366731B (en) | Propolis flavone, preparation method and uses in treating diabetes | |
| CN101396435A (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160406 Termination date: 20191212 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |